Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Your search for "vhl" returned 33 TaqMan® Gene Expression Assays
von Hippel-Lindau tumor suppressor
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]
|Protocol||Protocol: TaqMan® Gene Expression Assays||PDF, 2349.1 KB|
|App Note||Application Note: TaqMan® Gene Expression Assays Endogenous Controls||PDF, 493.8 KB|
|QRC||QRC: TaqMan® Gene Expression Assays||PDF, 200.9 KB|
|White Paper||Design Process for Gene Expression Assays||PDF, 943.6 KB|
|White Paper||Gene Expression Assay Performance Guarantee||PDF, 481.9 KB|
|White Paper||TaqMan® Assays shipped at ambient temperature retain their quality and stability||PDF, 3255.7 KB|
|Brochure||Understanding Your Shipment||PDF, 3726.3 KB|
|White Paper||Product Stability Study||PDF, 446.0 KB|
|Spreadsheet||Pathogen Assay Information||XLSX, 4231.7 KB|
Please enter the information below and press OK to send your cart to Core Services for purchase.